10x Genomics
233 hedge funds and large institutions have $2.45B invested in 10x Genomics in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 83 increasing their positions, 81 reducing their positions, and 54 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 81
1.11% less ownership
Funds ownership: 91.66% → 90.55% (-1.1%)
8% less funds holding
Funds holding: 254 → 233 (-21)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
20% less call options, than puts
Call options by funds: $6.44M | Put options by funds: $8.05M
37% less capital invested
Capital invested by funds: $3.91B → $2.45B (-$1.46B)
39% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$58.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.5M |
| 3 |
SW
SVB Wealth
Boston,
Massachusetts
|
+$38.3M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$37.1M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$30.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$94.6M |
| 2 |
BlackRock
New York
|
-$65.9M |
| 3 |
1WCM
12 West Capital Management
New York
|
-$56.5M |
| 4 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$31.1M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$20.7M |
TXG Hedge Fund Activity: Q3 2022 in Review
233 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q3 2022, worth a combined $2.45B — down 37% from $3.91B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of TXG and 33 opened new positions — a net loss of 21 holders — while 81 trimmed existing stakes and 83 added.
The largest buyer was Morgan Stanley, adding an estimated $58.3M. The largest seller was Fidelity Investments, cutting an estimated $94.6M.
- 233 institutional investors held 10x Genomics (TXG) as of Q3 2022, down from 254 in Q2 2022.
- Funds reported $2.45B of 10x Genomics stock for Q3 2022, down 37% quarter-over-quarter.
- 33 funds opened new 10x Genomics positions in Q3 2022 and 54 closed out, a net change of -21 holders.
- The largest 10x Genomics buyer in Q3 2022 was Morgan Stanley, an estimated $58.3M added.
- The largest 10x Genomics seller in Q3 2022 was Fidelity Investments, an estimated $94.6M sold.
Based on aggregated 13F filings for Q3 2022.